Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications

Autores
Pandi Perumal, Seithikurippu R.; Spence, David Warren; Verster, Joris C.; Srinivasan, Venkatramanujam; Brown, Gregory M.; Cardinali, Daniel Pedro; Hardeland, Rüdiger
Año de publicación
2011
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors. Ramelteon is the first melatonin receptor agonist approved by the Food and Drug Administration (FDA) for the treatment of insomnia characterized by sleep onset difficulties. Ramelteon is both a chronobiotic and a hypnotic that has been shown to promote sleep initiation and maintenance in various preclinical and in clinical trials. The efficacy and safety of ramelteon in patients with chronic insomnia was initially confirmed in short-term placebo-controlled trials. These showed little evidence of next-day residual effects, withdrawal symptoms or rebound insomnia. Other studies indicated that ramelteon lacked abuse potential and had a minimal risk of producing dependence or adverse effects on cognitive or psychomotor performance. A 6-month placebo-controlled international study and a 1-year open-label study in the USA demonstrated that ramelteon was effective and well tolerated. Other potential off-label uses of ramelteon include circadian rhythm sleep disorders such as shift-work and jet lag. At the present time the drug should be cautiously prescribed for short- term treatment only.
Fil: Pandi Perumal, Seithikurippu R.. College Street; Canadá
Fil: Spence, David Warren. No especifíca;
Fil: Verster, Joris C.. University of Utrecht; Países Bajos
Fil: Srinivasan, Venkatramanujam. Sri Sathya Sai Medical Educational and Research Foundation; India
Fil: Brown, Gregory M.. University of Toronto; Canadá. Centre for Addiction and Mental Health; Canadá
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Hardeland, Rüdiger. University of Goettingen; Alemania
Materia
CIRCADIAN RHYTHMS
HYPNOTIC
INSOMNIA
MELATONIN
RAMELTEON
SLEEP
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/192218
Acceder
id CONICETDig_917002c3162d4511b3f26949b55dacb7
oai_identifier_str oai:ri.conicet.gov.ar:11336/192218
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical ApplicationsPandi Perumal, Seithikurippu R.Spence, David WarrenVerster, Joris C.Srinivasan, VenkatramanujamBrown, Gregory M.Cardinali, Daniel PedroHardeland, RüdigerCIRCADIAN RHYTHMSHYPNOTICINSOMNIAMELATONINRAMELTEONSLEEPhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors. Ramelteon is the first melatonin receptor agonist approved by the Food and Drug Administration (FDA) for the treatment of insomnia characterized by sleep onset difficulties. Ramelteon is both a chronobiotic and a hypnotic that has been shown to promote sleep initiation and maintenance in various preclinical and in clinical trials. The efficacy and safety of ramelteon in patients with chronic insomnia was initially confirmed in short-term placebo-controlled trials. These showed little evidence of next-day residual effects, withdrawal symptoms or rebound insomnia. Other studies indicated that ramelteon lacked abuse potential and had a minimal risk of producing dependence or adverse effects on cognitive or psychomotor performance. A 6-month placebo-controlled international study and a 1-year open-label study in the USA demonstrated that ramelteon was effective and well tolerated. Other potential off-label uses of ramelteon include circadian rhythm sleep disorders such as shift-work and jet lag. At the present time the drug should be cautiously prescribed for short- term treatment only.Fil: Pandi Perumal, Seithikurippu R.. College Street; CanadáFil: Spence, David Warren. No especifíca;Fil: Verster, Joris C.. University of Utrecht; Países BajosFil: Srinivasan, Venkatramanujam. Sri Sathya Sai Medical Educational and Research Foundation; IndiaFil: Brown, Gregory M.. University of Toronto; Canadá. Centre for Addiction and Mental Health; CanadáFil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Hardeland, Rüdiger. University of Goettingen; AlemaniaSAGE Publications2011-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/192218Pandi Perumal, Seithikurippu R.; Spence, David Warren; Verster, Joris C.; Srinivasan, Venkatramanujam; Brown, Gregory M.; et al.; Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications; SAGE Publications; Journal of Central Nervous System Disease; 3; 4-2011; 51-651179-5735CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.4137/JCNSD.S1611info:eu-repo/semantics/altIdentifier/doi/10.4137/JCNSD.S1611info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:13:40Zoai:ri.conicet.gov.ar:11336/192218instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:13:40.497CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications
title Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications
spellingShingle Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications
Pandi Perumal, Seithikurippu R.
CIRCADIAN RHYTHMS
HYPNOTIC
INSOMNIA
MELATONIN
RAMELTEON
SLEEP
title_short Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications
title_full Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications
title_fullStr Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications
title_full_unstemmed Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications
title_sort Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications
dc.creator.none.fl_str_mv Pandi Perumal, Seithikurippu R.
Spence, David Warren
Verster, Joris C.
Srinivasan, Venkatramanujam
Brown, Gregory M.
Cardinali, Daniel Pedro
Hardeland, Rüdiger
author Pandi Perumal, Seithikurippu R.
author_facet Pandi Perumal, Seithikurippu R.
Spence, David Warren
Verster, Joris C.
Srinivasan, Venkatramanujam
Brown, Gregory M.
Cardinali, Daniel Pedro
Hardeland, Rüdiger
author_role author
author2 Spence, David Warren
Verster, Joris C.
Srinivasan, Venkatramanujam
Brown, Gregory M.
Cardinali, Daniel Pedro
Hardeland, Rüdiger
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv CIRCADIAN RHYTHMS
HYPNOTIC
INSOMNIA
MELATONIN
RAMELTEON
SLEEP
topic CIRCADIAN RHYTHMS
HYPNOTIC
INSOMNIA
MELATONIN
RAMELTEON
SLEEP
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors. Ramelteon is the first melatonin receptor agonist approved by the Food and Drug Administration (FDA) for the treatment of insomnia characterized by sleep onset difficulties. Ramelteon is both a chronobiotic and a hypnotic that has been shown to promote sleep initiation and maintenance in various preclinical and in clinical trials. The efficacy and safety of ramelteon in patients with chronic insomnia was initially confirmed in short-term placebo-controlled trials. These showed little evidence of next-day residual effects, withdrawal symptoms or rebound insomnia. Other studies indicated that ramelteon lacked abuse potential and had a minimal risk of producing dependence or adverse effects on cognitive or psychomotor performance. A 6-month placebo-controlled international study and a 1-year open-label study in the USA demonstrated that ramelteon was effective and well tolerated. Other potential off-label uses of ramelteon include circadian rhythm sleep disorders such as shift-work and jet lag. At the present time the drug should be cautiously prescribed for short- term treatment only.
Fil: Pandi Perumal, Seithikurippu R.. College Street; Canadá
Fil: Spence, David Warren. No especifíca;
Fil: Verster, Joris C.. University of Utrecht; Países Bajos
Fil: Srinivasan, Venkatramanujam. Sri Sathya Sai Medical Educational and Research Foundation; India
Fil: Brown, Gregory M.. University of Toronto; Canadá. Centre for Addiction and Mental Health; Canadá
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Hardeland, Rüdiger. University of Goettingen; Alemania
description Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors. Ramelteon is the first melatonin receptor agonist approved by the Food and Drug Administration (FDA) for the treatment of insomnia characterized by sleep onset difficulties. Ramelteon is both a chronobiotic and a hypnotic that has been shown to promote sleep initiation and maintenance in various preclinical and in clinical trials. The efficacy and safety of ramelteon in patients with chronic insomnia was initially confirmed in short-term placebo-controlled trials. These showed little evidence of next-day residual effects, withdrawal symptoms or rebound insomnia. Other studies indicated that ramelteon lacked abuse potential and had a minimal risk of producing dependence or adverse effects on cognitive or psychomotor performance. A 6-month placebo-controlled international study and a 1-year open-label study in the USA demonstrated that ramelteon was effective and well tolerated. Other potential off-label uses of ramelteon include circadian rhythm sleep disorders such as shift-work and jet lag. At the present time the drug should be cautiously prescribed for short- term treatment only.
publishDate 2011
dc.date.none.fl_str_mv 2011-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/192218
Pandi Perumal, Seithikurippu R.; Spence, David Warren; Verster, Joris C.; Srinivasan, Venkatramanujam; Brown, Gregory M.; et al.; Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications; SAGE Publications; Journal of Central Nervous System Disease; 3; 4-2011; 51-65
1179-5735
CONICET Digital
CONICET
url http://hdl.handle.net/11336/192218
identifier_str_mv Pandi Perumal, Seithikurippu R.; Spence, David Warren; Verster, Joris C.; Srinivasan, Venkatramanujam; Brown, Gregory M.; et al.; Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications; SAGE Publications; Journal of Central Nervous System Disease; 3; 4-2011; 51-65
1179-5735
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.4137/JCNSD.S1611
info:eu-repo/semantics/altIdentifier/doi/10.4137/JCNSD.S1611
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614056420311040
score 13.069144

Publicaciones similares